PNU-120596

PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research[1].

Product Specifications

CAS Number

[501925-31-1]

Product Name Alternative

NSC 216666

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/PNU-120596.html

Purity

99.49

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(Cl)=C(C=C1OC)OC)NC2=NOC(C)=C2

Molecular Formula

C13H14ClN3O4

Molecular Weight

311.72

Precautions

H302, H315, H320, H335

References & Citations

[1]Hurst RS, et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci, 2005, 25 (17), 4396-4405.|[2]Barron SC, et al. An allosteric modulator of alpha7 nicotinic receptors, N- (5-Chloro-2,4-dimethoxyphenyl) -N'- (5-methyl-3-isoxazolyl) -urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholine. Mol Pharmacol, 2009 76 (2), 253-263.|[3]Munro G, et al. The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol, 2012, doi: 10.1111/j.1476-5381.2012.02003.x